David Ho
Brooklyn, NYNPI 1366808719
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $134,919 of the $145,774 with a category attached, or 92.6%. Veru Inc. accounts for 92.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $134,919 and has fallen 93.2% since, to $9,230 in 2025.
Across 17 payments — averaging $8574.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veru Inc.$135K
- GSK$7K
- Regeneron$4K
Across 4 payments — averaging $187,586 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$486K
- Merck$264K
What the payments were for
- Consulting fees$10,8557%
- Speaking & faculty fees$134,91993%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.